- Home
- CTM vs IGMS Comparison
CTM vs IGMS Comparison
Compare CTM & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTM
- IGMS
- Stock Information
- Founded
- CTM 2019
- IGMS 1993
- Country
- CTM United States
- IGMS United States
- Employees
- CTM N/A
- IGMS N/A
- Industry
- CTM EDP Services
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- CTM Technology
- IGMS Health Care
- Exchange
- CTM Nasdaq
- IGMS Nasdaq
- Market Cap
- CTM 101.5M
- IGMS 82.1M
- IPO Year
- CTM N/A
- IGMS 2019
- Fundamental
- Price
- CTM $1.05
- IGMS $1.17
- Analyst Decision
- CTM Strong Buy
- IGMS Hold
- Analyst Count
- CTM 1
- IGMS 8
- Target Price
- CTM $3.00
- IGMS $6.00
- AVG Volume (30 Days)
- CTM 2.1M
- IGMS 205.4K
- Earning Date
- CTM 08-08-2025
- IGMS 08-13-2025
- Dividend Yield
- CTM N/A
- IGMS N/A
- EPS Growth
- CTM N/A
- IGMS N/A
- EPS
- CTM N/A
- IGMS N/A
- Revenue
- CTM $45,094,164.00
- IGMS $2,681,000.00
- Revenue This Year
- CTM $22.97
- IGMS $134.30
- Revenue Next Year
- CTM $3.76
- IGMS $22.37
- P/E Ratio
- CTM N/A
- IGMS N/A
- Revenue Growth
- CTM N/A
- IGMS 27.36
- 52 Week Low
- CTM $0.12
- IGMS $0.92
- 52 Week High
- CTM $2.83
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- CTM 45.48
- IGMS 42.70
- Support Level
- CTM $1.15
- IGMS $1.17
- Resistance Level
- CTM $1.44
- IGMS $1.40
- Average True Range (ATR)
- CTM 0.10
- IGMS 0.07
- MACD
- CTM -0.02
- IGMS -0.01
- Stochastic Oscillator
- CTM 17.19
- IGMS 4.17
About CTM Castellum Inc.
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.